Clinical Fellowships
Supports U.S. academic clinical fellowships to train physicians in the diagnosis, treatment, and research of Transthyretin-mediated Amyloidosis (ATTR) through multidisciplinary, patient-centered programs.
Funder: Alnylam Pharmaceuticals
Due Dates: August 28, 2026: Submission deadline for Clinical Fellowships application
Funding Amounts: Up to $95,000 per institution for a one-year clinical fellowship; funding supports fellow salary and benefits only.
Summary: Supports U.S. academic clinical fellowship programs to advance physician training in the diagnosis, treatment, and research of Transthyretin-mediated Amyloidosis (ATTR).
Description
This grant supports educational clinical programs at U.S. healthcare academic institutions focused on Transthyretin-mediated Amyloidosis (ATTR Amyloidosis). Its goal is to mentor and advance physician training in the diagnosis, treatment, and research of ATTR, fostering multidisciplinary collaboration to improve early recognition, optimize treatment pathways, and accelerate the translation of emerging science into patient-centered care. The program emphasizes skill development, assessment methodology, and collaboration across specialties, with a curriculum that must include both clinical care and research activities.
